Esperion Therapeutics, Inc. (NASDAQ:ESPR)‘s stock had its “neutral” rating reaffirmed by stock analysts at Bank of America Corporation in a research report issued to clients and investors on Friday, Marketbeat reports. They currently have a $60.00 price objective on the biopharmaceutical company’s stock. Bank of America Corporation’s price objective indicates a potential upside of 21.63% from the stock’s current price.

Several other brokerages have also recently weighed in on ESPR. Jefferies Group LLC initiated coverage on shares of Esperion Therapeutics in a research report on Monday, July 10th. They issued a “hold” rating and a $55.00 price target for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $60.00 price target (up previously from $45.00) on shares of Esperion Therapeutics in a research report on Monday, June 26th. UBS AG reaffirmed a “buy” rating and issued a $57.00 price target (up previously from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. Citigroup Inc. reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 22nd. Finally, Deutsche Bank AG initiated coverage on shares of Esperion Therapeutics in a research report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $42.51.

Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up 2.47% on Friday, hitting $49.33. The stock had a trading volume of 937,292 shares. The company has a 50 day moving average price of $47.09 and a 200-day moving average price of $35.27. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $57.38. The stock’s market cap is $1.27 billion.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.67) by $0.25. During the same period in the previous year, the firm earned ($0.62) EPS. On average, equities research analysts anticipate that Esperion Therapeutics will post ($7.29) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/13/esperion-therapeutics-inc-nasdaqespr-receives-neutral-rating-from-bank-of-america-corporation.html.

A number of large investors have recently bought and sold shares of ESPR. Quantbot Technologies LP purchased a new stake in Esperion Therapeutics during the first quarter worth approximately $158,000. C WorldWide Group Holding A S purchased a new stake in Esperion Therapeutics during the first quarter worth approximately $162,000. Aperio Group LLC purchased a new stake in Esperion Therapeutics during the second quarter worth approximately $249,000. Princeton Alpha Management LP purchased a new stake in Esperion Therapeutics during the first quarter worth approximately $205,000. Finally, Bank of Montreal Can boosted its stake in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares during the last quarter. 85.20% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.